Contracts › 75N93023C00003
75N93023C00003: To Develop an Orally Available Small Molecule Antiviral Drug, With Treatment of Yellow Fever Virus Infection As the Primary Indication.
Awarded to Baruch S. Blumberg Institute by National Institutes of Health (NIH).
$16.2Mobligated
$32.3Mpotential value
30 November 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93023C00003 |
|---|---|
| Awardee | Baruch S. Blumberg Institute |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | PA |
| Offers received | 10 |
| Period of performance | 15 November 2022 to 30 November 2027 |
| Potential end | 30 November 2027 |
| Estimated recompete solicitation | ~Q2 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record